Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1992 1
1993 1
1998 2
1999 1
2000 2
2002 2
2009 1
2010 1
2011 1
2012 4
2013 4
2014 3
2015 5
2016 10
2017 8
2018 6
2019 6
2020 6
2021 1
2022 2
2023 2
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. San-Miguel J, et al. Among authors: lendvai n. N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5. N Engl J Med. 2023. PMID: 37272512 Clinical Trial.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD. Lonial S, et al. Among authors: lendvai n. Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16. Lancet Oncol. 2020. PMID: 31859245 Clinical Trial.
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.
Cohen AD, Parekh S, Santomasso BD, Gállego Pérez-Larraya J, van de Donk NWCJ, Arnulf B, Mateos MV, Lendvai N, Jackson CC, De Braganca KC, Schecter JM, Marquez L, Lee E, Cornax I, Zudaire E, Li C, Olyslager Y, Madduri D, Varsos H, Pacaud L, Akram M, Geng D, Jakubowiak A, Einsele H, Jagannath S. Cohen AD, et al. Among authors: lendvai n. Blood Cancer J. 2022 Feb 24;12(2):32. doi: 10.1038/s41408-022-00629-1. Blood Cancer J. 2022. PMID: 35210399 Free PMC article.
Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.
Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, Wellner U, Malinoc A, Taschin E, Barbon G, Lanza V, Söderkvist P, Stenman A, Larsson C, Svahn F, Chen JL, Marquard J, Fraenkel M, Walter MA, Peczkowska M, Prejbisz A, Jarzab B, Hasse-Lazar K, Petersenn S, Moeller LC, Meyer A, Reisch N, Trupka A, Brase C, Galiano M, Preuss SF, Kwok P, Lendvai N, Berisha G, Makay Ö, Boedeker CC, Weryha G, Racz K, Januszewicz A, Walz MK, Gimm O, Opocher G, Eng C, Neumann HPH; European-American-Asian Pheochromocytoma-Paraganglioma Registry Study Group. Bausch B, et al. Among authors: lendvai n. JAMA Oncol. 2017 Sep 1;3(9):1204-1212. doi: 10.1001/jamaoncol.2017.0223. JAMA Oncol. 2017. PMID: 28384794 Free PMC article.
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma.
Jagannath S, Jackson CC, Schecter JM, Lendvai N, Sun H, Akram M, Patel N, Martin TG. Jagannath S, et al. Among authors: lendvai n. Expert Opin Biol Ther. 2024 May;24(5):339-350. doi: 10.1080/14712598.2024.2352591. Epub 2024 May 13. Expert Opin Biol Ther. 2024. PMID: 38738379 Review.
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
Raghunandan S, Pauly M, Blum WG, Qayed M, Dhodapkar MV, Elkhalifa M, Watkins B, Schoettler M, Horwitz E, Parikh S, Chandrakasan S, Leung K, Bryson E, Deeb L, Kaufman JL, Worthington-White D, Alazraki A, Schecter JM, Madduri D, Jackson CC, Zudaire E, Taraseviciute-Morris A, Babich A, Nesheiwat T, Vogel M, Lendvai N, Pacaud L, Williams KM. Raghunandan S, et al. Among authors: lendvai n. J Immunother Cancer. 2023 May;11(5):e006684. doi: 10.1136/jitc-2023-006684. J Immunother Cancer. 2023. PMID: 37137553 Free PMC article.
Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.
Bar N, Diels J, van Sanden S, Mendes J, Hernando T, Burnett H, Cost P, Schecter JM, Lendvai N, Patel N, Ishida T, Er J, Harrison SJ, Lopez-Muñoz N. Bar N, et al. Among authors: lendvai n. Curr Med Res Opin. 2024 Sep;40(9):1597-1603. doi: 10.1080/03007995.2024.2391112. Epub 2024 Aug 22. Curr Med Res Opin. 2024. PMID: 39129504
Minimal residual disease in multiple myeloma: bringing the bench to the bedside.
Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M, Landgren O. Mailankody S, et al. Among authors: lendvai n. Nat Rev Clin Oncol. 2015 May;12(5):286-95. doi: 10.1038/nrclinonc.2014.239. Epub 2015 Jan 27. Nat Rev Clin Oncol. 2015. PMID: 25622976 Free PMC article. Review.
63 results